4-dimethylaminophenol
Generic name
4-dimethylaminophenol
Brand name
ATC Code
V03AB27
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Cyanide intoxication |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
The effect in infants and toddlers has not been studied. Because methaemoglobin reductase is not completely effective in these children there is a serious danger of further increases in the methaemoglobin concentration and toxicity due to excess methaemoglobin. Target methaemoglobin concentration: 30-40%. At more than 50%, methylene blue is indicated.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ALL OTHER THERAPEUTIC PRODUCTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Antidotes | ||
|---|---|---|
| V03AB16 | ||
| V03AB24 | ||
| V03AB25 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE01 | ||
| V03AE02 | ||
| V03AE01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| Other therapeutic products | ||
|---|---|---|
| V03AX03 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| OTHER THERAPEUTIC PRODUCTS | ||
|---|---|---|
| V03AX03 | ||
Reference
- Rademaker C.M.A. et al., Geneesmiddelen-Formularium voor Kinderen, 2007
Changes
Therapeutic Drug Monitoring
Overdose
